Targeting acetylcholine signaling modulates persistent drug tolerance in EGFR-mutant lung cancer and impedes tumor relapse-Reference-Cited by-同舟云学术

Targeting acetylcholine signaling modulates persistent drug tolerance in EGFR-mutant lung cancer and impedes tumor relapse

Published:2022-10-17 Issue:20 Volume:132 Page:
ISSN:1558-8238
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:

Author:

Nie Meng,Chen Na,Pang Huanhuan^ORCID,Jiang Tao^ORCID,Jiang Wei,Tian Panwen,Yao LiAng^ORCID,Chen Yangzi,DeBerardinis Ralph J.,Li Weimin,Yu Qitao,Zhou Caicun,Hu Zeping

Funder

National Key R&D Program of China

National Natural Science Foundation of China

National Science and Technology Major Project for “Significant New Drugs Development

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://www.jci.org/articles/view/160152/files/pdf

Reference80 articles.

1. Lung cancer: current therapies and new targeted treatments

2. The great escape: tumour cell plasticity in resistance to targeted therapy;Boumahdi;Nat Rev Drug Discov,2019

3. Understanding and targeting resistance mechanisms in NSCLC

4. A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

5. The Cancer Stem Cell Marker Aldehyde Dehydrogenase Is Required to Maintain a Drug-Tolerant Tumor Cell Subpopulation

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting the peripheral neural-tumour microenvironment for cancer therapy;Nature Reviews Drug Discovery;2024-09-06

2. Metabolomic Profiling of Tumor Tissues Unveils Metabolic Shifts in Non-Small Cell Lung Cancer Patients with Concurrent Diabetes Mellitus;Journal of Proteome Research;2024-08-20

3. Drug tolerant persister cell plasticity in cancer: a revolutionary strategy for more effective anticancer therapies;Signal Transduction and Targeted Therapy;2024-08-14

4. PD-L1 induces autophagy and primary resistance to EGFR–TKIs in EGFR-mutant lung adenocarcinoma via the MAPK signaling pathway;Cell Death & Disease;2024-08-01

5. Blocking the WNT/β-catenin pathway in cancer treatment:pharmacological targets and drug therapeutic potential;Heliyon;2024-08